secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001193125-25-200159
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx launches $164M common stock offering at $10.00 per share to fund avexitide launch
--------------------------------------------------------------------------------

- Offering of 17.5M shares (2.625M option) at $10.00/share; net proceeds ~$164M, up to ~$188.7M.
- Proceeds to advance avexitide commercial readiness, R&D, working capital, and general corporate purposes.
- Underwriting led by Leerink Partners and Guggenheim Securities; expected closing September 11, 2025.
- Underwriters granted 30-day option to purchase up to 2.625M additional shares at offering price less discounts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312525200159/0001193125-25-200159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312525200159/d947193d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-200159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer